Applied BioCode Corporation (TPE:6598)

Market Cap	2.54B +29.3%
Revenue (ttm)	572.33M +50.0%
Net Income	-144.49M
EPS	-1.41
Shares Out	102.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	124,405
Open	25.30
Previous Close	24.75
Day's Range	24.65 - 25.35
52-Week Range	18.85 - 26.00
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	May 25, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Cayman Islands
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6598

Financial Performance

In 2025, Applied BioCode's revenue was 475.20 million, an increase of 38.52% compared to the previous year's 343.07 million. Losses were -201.20 million, -22.85% less than in 2024.